Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2081158 | 0.84 | PTPN1 (0.47) | PTPN1NR1H2NR1H3HDAC8CYP19A1 | |
| SCHEMBL6469137 | 0.83 | HSD11B1 (0.37) | PTPN1NR1H2NR1H3HDAC8NPC1 | |
| SCHEMBL21881597 | 0.83 | PTPN1 (0.54) | PTPN1NR1H2NR1H3HDAC8 | |
| SCHEMBL3697808 | 0.80 | PTPN1 (0.53) | PTPN1NR1H2NR1H3HDAC8CYP19A1 | |
| SCHEMBL21881601 | 0.80 | PTPN1 (0.53) | PTPN1NR1H2NR1H3HDAC8CYP19A1 | |
| SCHEMBL1202987 | 0.80 | PTPN1 (0.53) | PTPN1NR1H2NR1H3HDAC8HSD11B1 | |
| SCHEMBL23315480 | 0.80 | AGTR2 (0.42) | PTPN1HDAC8 | |
| SCHEMBL21881536 | 0.80 | AGTR2 (0.42) | PTPN1HDAC8 | |
| SCHEMBL31158754 | 0.77 | ESR2 (0.44) | NR1H2KCNH2TMEM97SIGMAR1 | |
| SCHEMBL23329941 | 0.77 | PTPN1 (0.58) | PTPN1NR1H2NR1H3HDAC8PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021445-B2 | Carboxylic acid derivative as AT2R receptor antagonist | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-06-01 | — | — | US | disclosed |
| EP-3620454-B1 | CARBOXYLIC ACID DERIVATIVE AS AT2R RECEPTOR ANTAGONIST | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-05-05 | — | — | EP | disclosed |
| US-20200102275-A1 | CARBOXYLIC ACID DERIVATIVE AS AT2R RECEPTOR ANTAGONIST | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102275-A1 | CARBOXYLIC ACID DERIVATIVE AS AT2R RECEPTOR ANTAGONIST | AGTR2, AGTR1, HCAR2 | PTPN1 1841/4885NR1H2 775/4885NR1H3 993/4885 |
| US-11021445-B2 | Carboxylic acid derivative as AT2R receptor antagonist | AGTR2, AGTR1, HCAR2 | PTPN1 1841/4885NR1H2 775/4885NR1H3 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.